BioSpace News Archive

Net Income Increases 52.6% to $4.8 Million, or $0.36 per Diluted Share, and Adjusted Diluted Earnings Per Share of $0.55

Cardiovascular Systems, Inc. announced that management will present and host investor meetings at the following three conferences

Hologic, Inc. announced that the Company will present at these upcoming investor conferences:

British company Optibiotix has signed an exclusive manufacturing and supply agreement with Indian Healthcare company Zeon for the use of OptiBiotix’s science-based weight management technology, SlimBiome®

Invitae Corporation announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced positive top-line results from the phase 3 heiGHt Trial, a randomized, open-label, active-controlled trial that compared once-weekly TransCon Growth Hormone (hGH) to a daily growth hormone (Genotropin®) in children with pediatric growth hormone deficiency (GHD)

Offering proceeds, along with balance sheet cash, expected to fund a debt reduction of ~$550 million

IQVIA uses advanced analytics and innovative technology, to find medium-to-high rates of flu in multiple U.S. markets; highest levels in parts of Montana, Nebraska and Texas

NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune.

Sanifit, a clinical-stage biopharmaceutical company focused on the treatment of conditions related to progressive vascular calcification, today announces the publication in the British Journal of Clinical Pharmacology of further data assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of its lead drug candidate SNF472 in haemodialysis (HD) patients.